The Cutaneous Angiosarcoma drugs in development market research report provides comprehensive information on the therapeutics under development for Cutaneous Angiosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cutaneous Angiosarcoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cutaneous Angiosarcoma and features dormant and discontinued products.
GlobalData tracks eight drugs in development for Cutaneous Angiosarcoma by eight companies/universities/institutes. The top development phase for Cutaneous Angiosarcoma is phase ii with seven drugs in that stage. The Cutaneous Angiosarcoma pipeline has seven drugs in development by companies and one by universities/ institutes. Some of the companies in the Cutaneous Angiosarcoma pipeline products market are: Amgen, Athenex and 3SBio.
The key targets in the Cutaneous Angiosarcoma pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1), and Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3).
The key mechanisms of action in the Cutaneous Angiosarcoma pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with two drugs in Phase II. The Cutaneous Angiosarcoma pipeline products include ten routes of administration with the top ROA being Intravenous and four key molecule types in the Cutaneous Angiosarcoma pipeline products market including Monoclonal Antibody, and Small Molecule.
Cutaneous Angiosarcoma overview
Cutaneous angiosarcoma (cAS) is a rare and aggressive subtype of soft tissue sarcoma with poor prognosis and suboptimal treatment options.
For a complete picture of Cutaneous Angiosarcoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
